论文部分内容阅读
本文测定了126例尿中CGMP的水平,其中原发性肝癌50例,原发性肝硬化15例,各型白血病14例、食道癌3例,肺癌1例,正常人53例。结果表明原发性肝癌患者尿中CGMP水平均值明显高于正常人组,原发性肝癌不论其并发肝硬变或不并发肝硬变,不论其临床分型属单纯型还是硬变型,临床Ⅱ期或Ⅲ期,尿中CGMP值都显著高于正常人组,差异在统计学上非常显著,但不同类型和分期之间差异却不显著。原发性肝癌尿中CGMP水平的显著升高不是特异性的,因为在肝硬化、白血病及一些恶性肿瘤中也表现为CGMP水平的明显升高,它们之间差异并不显著,因此我们认为CGMP的检测不能作为原发性肝癌的早诊指标。
This article measured 126 cases of urinary CGMP levels, including 50 cases of primary liver cancer, 15 cases of primary cirrhosis, 14 cases of various types of leukemia, 3 cases of esophageal cancer, 1 case of lung cancer, 53 cases of normal people. The results showed that the mean value of CGMP in urine of patients with primary liver cancer was significantly higher than that in the normal group. Primary liver cancer had no cirrhosis or cirrhosis, regardless of whether the clinical classification was simple or hard. Clinical II The urinary CGMP values were significantly higher than those in the normal group at either phase III or phase III. The difference was statistically significant, but the differences between different types and stages were not significant. The significant elevation of CGMP levels in urine of primary hepatocellular carcinoma is not specific, because in liver cirrhosis, leukemia, and some malignant tumors, there is also a significant increase in CGMP levels, and the difference between them is not significant, so we believe that CGMP The test cannot be used as a predictor of early diagnosis of primary liver cancer.